BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (JSMD194) to Treat Relapsed or Persistent Multiple Myeloma
- Status
- TERMINATED
- Phase
- PHASE1
Clinical Trials Related to Cyclophosphamide
Related studies linked through entity extraction aliases.
A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer
- Status
- TERMINATED
- Phase
- PHASE3
Neo-adjuvant Chemotherapy With Letrozole in Patients With Estrogen Receptor Positive/HER-2 Negative Breast Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE3
CYCLONES - CYClophosphamide LOw Dose and No Extra Steroid
- Status
- TERMINATED
- Phase
- NA
Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute Lymphoblastic Leukemia
- Status
- TERMINATED
- Phase
- PHASE2
Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
TIL-ACT After NMA Chemo with IL-2 and Nivo Rescue in Metastatic Melanoma (mMEL)
- Status
- COMPLETED
- Phase
- PHASE1
Total Marrow and Lymphoid Irradiation Before Donor Transplant and Cyclophosphamide in Treating Patients With Acute Myeloid Leukemia
- Status
- SUSPENDED
- Phase
- PHASE1
A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL
- Status
- COMPLETED
- Phase
- PHASE1
CD19 T-CAR for Treatment of Children and Young Adults With r/r B-ALL
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
Modified T Cells, Chemotherapy, and Aldesleukin With or Without LV305 and CMB305 in Treating Participants With Advanced or Recurrent Sarcoma
- Status
- COMPLETED
- Phase
- PHASE1
LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With Myeloma
- Status
- TERMINATED
- Phase
- PHASE1
CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
- Status
- COMPLETED
- Phase
- PHASE1
Pom-dex Versus Pom-Cyclo-dex in MM Patients With Biochemical or Clinical Relapse, During Lena Maintenance Treatment
- Status
- TERMINATED
- Phase
- PHASE3
AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Non Hodgkin Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Combination Chemotherapy, Total Body Irradiation, and Donor Blood Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis
- Status
- COMPLETED
- Phase
- EARLY_PHASE1
Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors
- Status
- TERMINATED
- Phase
- PHASE1
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
- Status
- RECRUITING
- Phase
- PHASE2